Mechanism: Vaccine containing nine HLA class I‐ and class II‐restricted peptides derived from both mutated and non‐mutated AML/LPC antigens that are tumour‐exclusive resulting in CD8+and Th1 CD4+T cell responses. Here, CD8A is linked to neoplasm.